Scholarlink

Background <p>Ceralasertib is an oral, selective, and potent inhibitor of ATR serine/threonine kinase, a key protein involved in cell cycle checkpoint regulation and DNA damage response. We report preliminary safety, tolerability, and pharmacokinetic data of ceralasertib monotherapy in Japanese patients with advanced solid tumors.</p> Methods <p>In this phase 1, open-label study, patients orally received ceralasertib twice daily 240&#xa0;mg on days 1–7 (Cohort 1) or 160&#xa0;mg on days 1–14 (Cohort 2) of a 28-day cycle, respectively; both cohorts also received a single ceralasertib dose 4&#xa0;days before Cycle 1. Patients were aged ≥ 18&#xa0;years with solid malignancies refractory to standard therapies or for which no standard therapy exists. The primary objective was to determine ceralasertib safety; secondary objectives included assessing antitumor activity and pharmacokinetics. Exploratory objectives included biomarker analysis.</p> Results <p>Twelve of 14 patients screened received ceralasertib. At data cutoff (August 17, 2023), all 12 patients had experienced at least one treatment-emergent adverse event (AE; grade ≥ 3, <i>n</i> = 3). One patient in each cohort had a dose-limiting toxicity; no AE-related deaths were reported. In total, 6 patients had a best objective response of stable disease (Cohort 1, <i>n</i> = 2; Cohort 2, <i>n</i> = 4). A trend suggesting dose-proportional increases in exposure following single and multiple administration of ceralasertib was observed.</p> Conclusion <p>Ceralasertib monotherapy was generally well tolerated in Japanese patients with advanced solid tumors. The small number of patients enrolled prevents definitive conclusions on the efficacy of ceralasertib monotherapy to be made.</p> Trial registration <p>ClinicalTrials.gov, NCT05469919. Registration date: May 18, 2022.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月6日

查看全文
  • Yasutoshi Kuboki,
  • Nobuaki Matsubara,
  • Hiromichi Nakajima,
  • Takao Fujisawa,
  • Takafumi Koyama,
  • Jun Sato,
  • Yuki Katsuya,
  • Aleksandra Kmieciak,
  • Daniel Slade,
  • Kiyomi Iwata,
  • Yusuke Takahashi,
  • Masahiro Nii,
  • Kosho Murayama,
  • Toshio Kawata,
  • Hisashi Kawasumi,
  • Noboru Yamamoto

摘要

Background

Ceralasertib is an oral, selective, and potent inhibitor of ATR serine/threonine kinase, a key protein involved in cell cycle checkpoint regulation and DNA damage response. We report preliminary safety, tolerability, and pharmacokinetic data of ceralasertib monotherapy in Japanese patients with advanced solid tumors.

Methods

In this phase 1, open-label study, patients orally received ceralasertib twice daily 240 mg on days 1–7 (Cohort 1) or 160 mg on days 1–14 (Cohort 2) of a 28-day cycle, respectively; both cohorts also received a single ceralasertib dose 4 days before Cycle 1. Patients were aged ≥ 18 years with solid malignancies refractory to standard therapies or for which no standard therapy exists. The primary objective was to determine ceralasertib safety; secondary objectives included assessing antitumor activity and pharmacokinetics. Exploratory objectives included biomarker analysis.

Results

Twelve of 14 patients screened received ceralasertib. At data cutoff (August 17, 2023), all 12 patients had experienced at least one treatment-emergent adverse event (AE; grade ≥ 3, n = 3). One patient in each cohort had a dose-limiting toxicity; no AE-related deaths were reported. In total, 6 patients had a best objective response of stable disease (Cohort 1, n = 2; Cohort 2, n = 4). A trend suggesting dose-proportional increases in exposure following single and multiple administration of ceralasertib was observed.

Conclusion

Ceralasertib monotherapy was generally well tolerated in Japanese patients with advanced solid tumors. The small number of patients enrolled prevents definitive conclusions on the efficacy of ceralasertib monotherapy to be made.

Trial registration

ClinicalTrials.gov, NCT05469919. Registration date: May 18, 2022.